KCNAB2

Across TCGA pan-cancer cohorts, KCNAB2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated KCNAB2 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher KCNAB2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KCNAB2 expression acts as an unfavorable survival marker.

LIHC, LUSC, and PRAD are the cancer types where KCNAB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.016	0.781	<.001	30	view →
LUSC	DFS	Median	All	0.148	0.712	.005	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

KCNAB2–LIHC (OS)

Open the LIHC breakdown →